aclarubicin

Aclarubicin (also known as aclacinomycin A, 阿克拉霉素) is an anthracycline antitumor antibiotic derived from Streptomyces galilaeus. It is a lipophilic compound that rapidly enters cells and maintains high intracellular concentrations. Its primary mechanism of action involves intercalating into DNA, thereby inhibiting nucleic acid synthesis—especially RNA synthesis—and blocking cell cycle progression in late G1 and S phases. Unlike other anthracyclines, aclarubicin inhibits both topoisomerase I and II, which may contribute to its efficacy in certain cancers resistant to other agents[1][2][4][5][8]. It has been used mainly for the treatment of hematological malignancies such as acute myeloid leukemia (AML), malignant lymphoma, gastric cancer, lung cancer, ovarian cancer, and other solid tumors[5][6]. The drug was previously approved in Europe but discontinued due to limited use; it remains available in China[5].

Brand names

aclarubicin

Other names

阿克拉霉素阿柔比星安乐霉素盐酸阿柔比星